Prevention of contrast-induced AKI: A review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 9, 2013, Pages 1618-1631

  Weisbord, Steven D ^a,b   Gallagher, Martin ^c   Kaufman, James ^a,d   Cass, Alan ^c   Parikh, Chirag R ^e,f   Chertow, Glenn M ^g   Shunk, Kendrick A ^a,h   Mccullough, Peter A ⁱ   Fine, Michael J ^a,b   Mor, Maria K ^a   Lew, Robert A ^d   Huang, Grant D ^j   Conner, Todd A ^k   Brophy, Mary T ^d   Lee, Joanne ^c   Soliva, Susan ^d   Palevsky, Paul M ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^d VA BOSTON HEALTHCARE SYSTEM   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ PROVIDENCE HOSPITAL   (United States)

^j DEPARTMENT OF VETERANS AFFAIRS   (United States)

^k University of New Mexico   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; BICARBONATE; CONTRAST MEDIUM; IOHEXOL; IOXAGLIC ACID; PLACEBO; SODIUM CHLORIDE;

ACUTE KIDNEY FAILURE; ANGIOGRAPHY; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DRUG BIOAVAILABILITY; GLOMERULUS FILTRATION RATE; HIGH RISK POPULATION; HUMAN; KIDNEY FUNCTION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; SAMPLE SIZE; SYSTEMATIC REVIEW (TOPIC);

ACETYLCYSTEINE; ACUTE KIDNEY INJURY; ADMINISTRATION, INTRAVENOUS; ANGIOGRAPHY; CONTRAST MEDIA; FREE RADICAL SCAVENGERS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SODIUM BICARBONATE;

EID: 84883711324     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.11161012     Document Type: Article

References (97)

1. Goldenberg I, Chonchol M, Guetta V: Reversible acute kidney injury following contrast exposure and the risk of long-term mortality. Am J Nephrol 29: 136-144, 2009
2. James MT, Ghali WA, Tonelli M, Faris P, Knudtson ML, Pannu N, Klarenbach SW, Manns BJ, Hemmelgarn BR: Acute kidney injury following coronary angiography is associated with a long-term decline in kidney function. Kidney Int 78: 803-809, 2010
3. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR Jr: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105: 2259-2264, 2002
4. Weisbord SD, Palevsky PM: Prevention of contrast-induced nephropathy with volume expansion. Clin J Am Soc Nephrol 3: 273-280, 2008
5. Briguori C, Airoldi F, D'Andrea D, Bonizzoni E, Morici N, Focaccio A, Michev I, Montorfano M, Carlino M, Cosgrave J, Ricciardelli B, Colombo A: Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): A randomized comparison of 3 preventive strategies. Circulation 115: 12111217, 2007
6. Masuda M, Yamada T, Mine T, Morita T, Tamaki S, Tsukamoto Y, Okuda K, Iwasaki Y, Hori M, Fukunami M: Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. Am J Cardiol 100: 781-786, 2007
7. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, Bersin RM, Van Moore A, Simonton CA 3rd, Rittase RA, Norton HJ, Kennedy TP: Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 291: 2328-2334, 2004
8. Motohiro M, Kamihata H, Tsujimoto S, Seno T, Manabe K, Isono T, Sutani Y, Yuasa F, Iwasaka T: A new protocol using sodium bicarbonate for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Am J Cardiol 107: 1604-1608, 2011
9. Ozcan EE, Guneri S, Akdeniz B, Akyildiz IZ, Senaslan O, Baris N, Aslan O, Badak O: Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A singlecenter prospective controlled trial. Am Heart J 154: 539-544, 2007
10. Pakfetrat M, Nikoo MH, Malekmakan L, Tabandeh M, Roozbeh J, Nasab MH, Ostovan MA, Salari S, Kafi M, Vaziri NM, Adl F, Hosseini M, Khajehdehi P: A comparison of sodium bicarbonate infusion versus normal saline infusion and its combination with oral acetazolamide for prevention of contrast-induced nephropathy: A randomized, double-blind trial. Int Urol Nephrol 41: 629-634, 2009
11. Recio-Mayoral A, Chaparro M, Prado B, Cózar R, Méndez I, Banerjee D, Kaski JC, Cubero J, Cruz JM: The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: The RENO Study. J Am Coll Cardiol 49: 12831288, 2007
12. Maioli M, Toso A, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, Bellandi F: Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol 52: 599-604, 2008
13. Adolph E, Holdt-Lehmann B, Chatterjee T, Paschka S, Prott A, Schneider H, Koerber T, Ince H, Steiner M, Schuff-Werner P, Nienaber CA: Renal Insufficiency Following Radiocontrast Exposure Trial (REINFORCE): A randomized comparison of sodium bicarbonate versus sodium chloride hydration for the prevention of contrast-induced nephropathy. Coron Artery Dis 19: 413-419, 2008
14. Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, Ree M, Shah AI, Burchette RJ: Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: A randomized trial. JAMA 300: 1038-1046, 2008
15. Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, Golia B, Ricciardelli B, Condorelli G; REMEDIAL II Investigators: Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation 124: 1260-1269, 2011
16. Castini D, Lucreziotti S, Bosotti L, Salerno Uriarte D, Sponzilli C, Verzoni A, Lombardi F: Prevention of contrast-induced nephropathy: A single center randomized study. Clin Cardiol 33: E63-E68, 2010
17. Lee SW, Kim WJ, Kim YH, Park SW, Park DW, Yun SC, Lee JY, Kang SJ, Lee CW, Lee JH, Choi SW, Seong IW, Suh J, Cho YH, Lee NH, Cheong SS, Yoo SY, Lee BK, Lee SG, Hyon MS, Shin WY, Lee SW, Jang JS, Park SJ: Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT Trial). Am J Cardiol 107: 1447-1452, 2011
18. Maioli M, Toso A, Leoncini M, Micheletti C, Bellandi F: Effects of hydration in contrast-induced acute kidney injury after primary angioplasty: A randomized, controlled trial. Circ Cardiovasc Interv 4: 456-462, 2011
19. Shavit L, Korenfeld R, Lifschitz M, Butnaru A, Slotki I: Sodium bicarbonate versus sodium chloride and oral N-acetylcysteine 0for the prevention of contrast-induced nephropathy in advanced chronic kidney disease. J Interv Cardiol 22: 556-563, 2009
20. Vasheghani-Farahani A, Sadigh G, Kassaian SE, Khatami SM, Fotouhi A, Razavi SA, Mansournia MA, Yamini-Sharif A, Amirzadegan A, Salarifar M, Sadeghian S, Davoodi G, Borumand MA, Esfehani FA, Darabian S: Sodium bicarbonate plus isotonic saline versus saline for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: A randomized controlled trial. Am J Kidney Dis 54: 610-618, 2009
21. Rosenstock JL, Gilles E, Geller AB, Panagopoulos G, Mathew S, Malieckal D, DeVita MV, Michelis MF: Impact of heart failure on the incidence of contrast-induced nephropathy in patients with chronic kidney disease. Int Urol Nephrol 42: 1049-1054, 2010
22. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ: A rapid protocol for the prevention of contrast-induced renal dysfunction: The RAPPID study. J Am Coll Cardiol 41: 2114-2118, 2003
23. Balderramo DC, Verdu MB, Ramacciotti CF, Cremona LS, Lemos PA, Orías M, Eduardo M Jr: Renoprotective effect of high periprocedural doses of oral N-acetylcysteine in patients scheduled to undergo a same-day angiography. Rev Fac Cien Med Univ Nac Cordoba 61: 13-19, 2004
24. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW: Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 89: 356-358, 2002
25. Drager LF, Andrade L, Barros de Toledo JF, Laurindo FR, Machado César LA, Seguro AC: Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: Decrease in oxidant stressmediated renal tubular injury. Nephrol Dial Transplant 19: 1803-1807, 2004
26. Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, Fan K, Lee CH, Lam WF: Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: A randomized controlled trial. JAMA 289: 553-558, 2003
27. MacNeill BD, Harding SA, Bazari H, Patton KK, Colon-Hernadez P, DeJoseph D, Jang IK: Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography. Catheter Cardiovasc Interv 60: 458-461, 2003
28. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbiocchi F, Montorsi P, Veglia F, Bartorelli AL: N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 354: 27732782, 2006
29. Miner SE, Dzavik V, Nguyen-Ho P, Richardson R, Mitchell J, Atchison D, Seidelin P, Daly P, Ross J, McLaughlin PR, Ing D, Lewycky P, Barolet A, Schwartz L: N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J 148: 690-695, 2004
30. Ochoa A, Pellizzon G, Addala S, Grines C, Isayenko Y, Boura J, Rempinski D, O'Neill W, Kahn J: Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention. J Interv Cardiol 17: 159-165, 2004
31. Shyu KG, Cheng JJ, Kuan P: Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 40: 13831388, 2002
32. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W: Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343: 180-184, 2000
33. Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, Bajwa TK: Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 57: 279-283, 2002
34. Amini M, Salarifar M, Amirbaigloo A, Masoudkabir F, Esfahani F: N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: A randomized clinical trial. Trials 10: 45, 2009
35. Azmus AD, Gottschall C, Manica A, Manica J, Duro K, Frey M, BulcaoL,LimaC:Effectivenessofacetylcysteineinpreventionof contrast nephropathy. J Invasive Cardiol 17: 80-84, 2005
36. Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G, Lepore S, Librera M, Villari B, Colombo A, Ricciardelli B: Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 40: 298-303, 2002
37. Carbonell N, Blasco M, Sanjuán R, Pérez-Sancho E, Sanchis J, Insa L, Bodí V, Núnez J, García-Ramón R, Miguel A: Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: A randomised trial. Int J Cardiol 115: 57-62, 2007
38. Coyle LC, Rodriguez A, Jeschke RE, Simon-Lee A, Abbott KC, Taylor AJ: Acetylcysteine In Diabetes (AID): A randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics. Am Heart J 151: 1032e9-1032e12, 2006
39. Durham JD, Caputo C, Dokko J, Zaharakis T, Pahlavan M, Keltz J, Dutka P, Marzo K, Maesaka JK, Fishbane S: A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 62: 2202-2207, 2002
40. Fung JW, Szeto CC, Chan WW, Kum LC, Chan AK, Wong JT, Wu EB, Yip GW, Chan JY, Yu CM, Woo KS, Sanderson JE: Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: A randomized trial. Am J Kidney Dis 43: 801-808, 2004
41. Goldenberg I, Shechter M, Matetzky S, Jonas M, Adam M, Pres H, Elian D, Agranat O, Schwammenthal E, Guetta V: Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J 25: 212-218, 2004
42. Gomes VO, Poli de Figueredo CE, Caramori P, Lasevitch R, Bodanese LC, Araújo A, Roedel AP, Caramori AP, Brito FS Jr, Bezerra HG, Nery P, Brizolara A: N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: A multicentre clinical trial. Heart 91: 774-778, 2005
43. Kefer JM, Hanet CE, Boitte S, Wilmotte L, De Kock M: Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: Which benefit for which patient? Acta Cardiol 58: 555-560, 2003
44. Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE: Acetylcysteine in the prevention of contrastinduced nephropathy after coronary angiography. Am Heart J 146: E23, 2003
45. Rashid ST, Salman M, Myint F, Baker DM, Agarwal S, Sweny P, Hamilton G: Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: A randomized controlled trial of intravenous N-acetylcysteine. J Vasc Surg 40: 1136-1141, 2004
46. Sandhu C, Belli AM, Oliveira DB: The role of N-acetylcysteine in the prevention of contrast-induced nephrotoxicity. Cardiovasc Intervent Radiol 29: 344-347, 2006
47. Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al Shamari A, Sutander A, Williams T, Fox RS, Levin A: A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: Lack of effect. Am Heart J 148: 422-429, 2004
48. Awal A, Ahsan SA, Siddique MA, Banerjee S, Hasan MI, Zaman SM, Arzu J, Subedi B: Effect of hydration with or without n-acetylcysteine on contrast induced nephropathy in patients undergoing coronary angiography and percutaneous coronary intervention. Mymensingh Med J 20: 264-269, 2011
49. Sar F, Saler T, Ecebay A, Saglam ZA, Ozturk S, Kazancioglu R: The efficacy of N-acetylcysteine in preventing contrast-induced nephropathy in type 2 diabetic patients without nephropathy. J Nephrol 23: 478-482, 2010
50. Sadat U, Walsh SR, Norden AG, Gillard JH, Boyle JR: Does oral N-acetylcysteine reduce contrast-induced renal injury in patients with peripheral arterial disease undergoing peripheral angiography? A randomized-controlled study. Angiology 62: 225-230, 2011
51. Kinbara T, Hayano T, Ohtani N, Furutani Y, Moritani K, Matsuzaki M: Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy. J Cardiol 55: 174-179, 2010
52. Boccalandro F, Amhad M, Smalling RW, Sdringola S: Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv 58: 336-341, 2003
53. Buyukhatipoglu H, Sezen Y, Yildiz A, Bas M, Kirhan I, Ulas T, Turan MN, Taskin A, Aksoy N: N-acetylcysteine fails to prevent renal dysfunction and oxidative stress after noniodine contrast media administration during percutaneous coronary interventions. Pol Arch Med Wewn 120: 383-389, 2010
54. Burns KE, Priestap F, Martin C: N-acetylcysteine in critically ill patients undergoing contrast-enhanced computed tomography: A randomized trial. Clin Nephrol 74: 323-326, 2010
55. Ferrario F, Barone MT, Landoni G, Genderini A, Heidemperger M, Trezzi M, Piccaluga E, Danna P, Scorza D: Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy-a randomized controlled study. Nephrol Dial Transplant 24: 3103-3107, 2009
56. Tanaka A, Suzuki Y, Suzuki N, Hirai T, Yasuda N, Miki K, Fujita M, Tanaka T: Does N-acetylcysteine reduce the incidence of contrast-induced nephropathy and clinical events in patients undergoing primary angioplasty for acute myocardial infarction? Intern Med 50: 673-677, 2011
57. Thiele H, Hildebrand L, Schirdewahn C, Eitel I, Adams V, Fuernau G, Erbs S, Linke A, Diederich KW, Nowak M, Desch S, Gutberlet M, Schuler G: Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate Percutaneous Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol 55: 2201-2209, 2010
58. Droppa M, Desch S, Blase P, Eitel I, Fuernau G, Schuler G, Adams V, Thiele H: Impact of N-acetylcysteine on contrast-induced nephropathy defined by cystatin C in patients with ST-elevation myocardial infarction undergoing primary angioplasty. Clin Res Cardiol 100: 1037-1043, 2011
59. ACT Investigators: Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: Main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation 124: 1250-1259, 2011
60. Brar SS, Hiremath S, Dangas G, Mehran R, Brar SK, Leon MB: Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: A systematic review and meta-analysis. Clin J Am Soc Nephrol 4: 1584-1592, 2009
61. Brown JR, Block CA, Malenka DJ, O'Connor GT, Thompson CA: Sodium bicarbonate plus N-acetylcysteine prophylaxis: a meta-analysis. JACC Cardiovasc Interv 2: 11161124, 2009
62. Ho KM, Morgan 0DJ: Use of isotonic sodium bicarbonate to prevent radiocontrast nephropathy in patients with mild pre-existing renal impairment: A meta-analysis. Anaesth Intensive Care 36: 646-653, 2008
63. Hogan SE, L'Allier P, Chetcuti S, Grossman PM, Nallamothu BK, Duvernoy C, Bates E, Moscucci M, Gurm HS: Current role of sodium bicarbonate-based preprocedural hydration for the prevention of contrast-induced acute kidney injury: A metaanalysis. Am Heart J 156: 414-421, 2008
64. Hoste EA, De Waele JJ, Gevaert SA, Uchino S, Kellum JA: Sodium bicarbonate for prevention of contrast-induced acute kidney injury: A systematic review and meta-analysis. Nephrol Dial Transplant 25: 747-758, 2010
65. Joannidis M, Schmid M, Wiedermann CJ: Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate: A meta-analysis. Wien Klin Wochenschr 120: 742-748, 2008
66. Kanbay M, Covic A, Coca SG, Turgut F, Akcay A, Parikh CR: Sodium bicarbonate for the prevention of contrast-induced nephropathy: A meta-analysis of 17 randomized trials. Int Urol Nephrol 41: 617-627, 2009
67. Meier P, Ko DT, Tamura A, Tamhane U, Gurm HS: Sodium bicarbonate-based hydration prevents contrast-induced ne0phropathy: A meta-analysis. BMC Med 7: 23, 2009
68. Nava Neethan SD, Singh S, Appasamy S, Wing RE, Sehgal AR:Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: A systematic review and meta-analysis. Am J Kidney Dis 53: 617-627, 2009
69. Zoungas S, Ninomiya T, Huxley R, Cass A, Jardine M, Gallagher M, Patel A, Vasheghani-Farahani A, Sadigh G, Perkovic V: Systematic review: Sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Ann Intern Med 151: 631-638, 2009
70. Kunadian V, Zaman A, Spyridopoulos I, Qiu W: Sodium bicarbonate for the prevention of contrast induced nephropathy: A meta-analysis of published clinical trials. Eur J Radiol 79: 48-55, 2011
71. Trivedi H, Nadella R, Szabo A: Hydration with sodium bicarbonate for the prevention of contrast-induced nephropathy: A meta-analysis of randomized controlled trials. Clin Nephrol 74: 288-296, 2010
72. Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ: Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: A meta-analysis of randomized, controlled trials. Am J Kidney Dis 43: 1-9, 2004
73. Bagshaw SM, Ghali WA: Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: A systematic review and meta-analysis. BMC Med 2: 38, 2004
74. Birck R, Krzossok S, Markowetz F, Schnulle P, van der Woude FJ, Braun C: Acetylcysteine for prevention of contrast nephropathy: Meta-analysis. Lancet 362: 598-603, 2003
75. Duong MH, MacKenzie TA, Malenka DJ: N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: Comprehensive meta-analysis. Catheter Cardiovasc Interv 64: 471-479, 2005
76. Faddy SC: Significant statistical heterogeneity in a meta-analysis of the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 94: 414, 2004
77. Gawenda M, M oller A, Wassmer G, Brunkwall J: [Prophylaxis of contrast-induced nephropathy with N-acetylcysteine]. Zentralbl Chir 132: 227-231, 2007
78. Gonzales DA, Norsworthy KJ, Kern SJ, Banks S, Sieving PC, Star RA, Natanson C, Danner RL: A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: Unsupervised clustering to resolve heterogeneity. BMC Med 5: 32, 2007
79. Guru V, Fremes SE: The role of N-acetylcysteine in preventing radiographic contrast-induced nephropathy. Clin Nephrol 62: 77-83, 2004
80. Isenbarger DW, Kent SM, O'Malley PG: Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for 0prevention of contrast nephropathy. Am J Cardiol 92: 14541458, 2003
81. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC: Metaanalysis: Effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 148: 284-294, 2008
82. Kshirsagar AV, Poole C, Mottl A, Shoham D, Franceschini N, Tudor G, Agrawal M, Denu-Ciocca C, Magnus Ohman E, Finn WF: N-acetylcysteine for the prevention of radiocontrast induced nephropathy: A meta-analysis of prospective controlled trials. J Am Soc Nephrol 15: 761-769, 2004
83. Liu R, Nair D, Ix J, Moore DH, Bent S: N-acetylcysteine for the 0prevention of contrast-induced nephropathy. A systematic review and meta-analysis. J Gen Intern Med 20: 193-200, 2005
84. Misra D, Leibowitz K, Gowda RM, Shapiro M, Khan IA: Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: A meta-analysis. Clin Cardiol 27: 607-610, 2004
85. Nallamothu BK, Shojania KG, Saint S, Hofer TP, Humes HD, Moscucci M, Bates ER: Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am J Med 117: 938-947, 2004
86. Pannu N, Manns B, Lee H, Tonelli M: Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 065: 1366-1374, 2004
87. Trivedi H, Daram S, Szabo A, Bartorelli AL, Marenzi G: Highdose N-acetylcysteine for the prevention of contrast-induced nephropathy. Am J Med 122: e9-e874, 2009
88. Zagler A, Azadpour M, Mercado C, Hennekens CH: N-acetylcysteine and contrast-induced nephropathy: A metaanalysis of 13 randomized trials. Am Heart J 151: 140-145, 2006
89. Weisbord SD, Mor MK, Resnick AL, Hartwig KC, Sonel AF, Fine MJ, Palevsky PM: Prevention, incidence, and outcomes of contrast-induced acute kidney injury. Arch Intern Med 168: 1325-1332, 2008
90. Chertow GM, Palevsky PM, Greene T: Studying the prevention of acute kidney injury: Lessons from an 18th-century mathematician. Clin J Am Soc Nephrol 1: 1124-1127, 2006
91. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH: 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 124: e574-e651, 2011
92. Kidney Disease Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group: KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2: 1-126, 2012
93. James MT, Ghali WA, Knudtson ML, Ravani P, Tonelli M, Faris P, Pannu N, Manns BJ, Klarenbach SW, Hemmelgarn BR; Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators: Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. Circulation 123: 409-416, 2011
94. Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM, Pichard AD, Satler LF, Leon MB: The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 36: 1542-1548, 2000
95. Vaitkus PT, Brar C: N-acetylcysteine in the prevention of contrastinduced nephropathy: Publication bias perpetuated by metaanalyses. Am Heart J 153: 275-280, 2007
96. Chou SH, Wang ZJ, Kuo J, Cabarrus M, Fu Y, Aslam R, Yee J, Zimmet JM, Shunk K, Elicker B, Yeh BM: Persistent renal enhancement after intra-arterial versus intravenous iodixanol administration. Eur J Radiol 80: 378-386, 2011
97. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO: 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 54: 2205-2241, 2009